Caas Capital Management LP Spring Works Therapeutics, Inc. Transaction History

Caas Capital Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$53.3 - $75.84 $6 Million - $8.54 Million	-112,643 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$62.66 - $88.26 $7.06 Million - $9.94 Million	112,643 New	112,643 $7.15 Million
Q2 2021 Aug 16, 2021	SELL	$67.45 - $85.63 $15.2 Million - $19.3 Million	-224,886 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$65.1 - $93.59 $5.88 Million - $8.46 Million	90,364 Added 67.17%	224,886 $16.5 Million
Q4 2020 Feb 12, 2021	BUY	$48.36 - $77.92 $6.51 Million - $10.5 Million	134,522 New	134,522 $9.76 Million

238

69.8M

144K

257K

Ticker SWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,401,100
Market Cap $2.6B
Description
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...

Get notified when there are updates to the investment portfolio of Caas Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Caas Capital Management LP with notifications on news.